This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Kidney cancer	L-2-hydroxyglutarate dehydrogenase (L2HGDH)	<i>In vitro</i> studies suggest agonizing L2HGDH could help treat renal cell carcinoma (RCC). In primary RCC tumor samples, levels of L2HGDH were lower and levels of its substrate, L-2-hydroxyglutarate (L-2-HG), were higher than in normal kidney tissue. In RCC cell lines, lentiviral-mediated expression of <i>L2HGDH</i> decreased L-2-HG levels, cancer cell proliferation and colony formation compared with no <i>L2HGDH</i> expression. Next steps could include identifying strategies to augment L2HGDH levels or activity in patients with cancer.	Patent and licensing status unavailable	Shim, E.-H. <i>et al. Cancer Discov.</i> ; published online Sept. 2, 2014; doi:10.1158/2159-8290.CD-13-0696 Contact: Sunil Sudarshan, The University of Alabama at Birmingham, Birmingham, Ala. e-mail: sudarshan@uab.edu
<i>SciBX</i> 7(41); doi:10.1038/scibx.2014.1205 Published online Oct. 23, 2014				